Toxicol Appl Pharmacol 262(1):1-10
Publication Date: April 21, 2012
Product Type: iCell Cardiomyocytes
iCell Cardiomyocytes were used to support the assertion that HER-2 targeted liposomal doxorubicin does not induce cardiotoxicity. Data were included in an Investigational New Drug (IND) application submitted to the FDA.
iCell Cardiomyocytes provided a relevant human model system to advance a new drug candidate through the drug development pipeline. This is the first known instance of data generated using an iPS cell-derived model being used to support an IND filing to the FDA.